Find the funding your business is owed

Call for proposals to establish a coordinated European Research Area (ERA) policy action to accelerate the development, validation, and uptake of New Approach Methodologies (NAMs) in biomedical research and regulatory testing.

European Union

€2.9Mnon-repayable

Call for proposals to establish a coordinated European Research Area (ERA) policy action to accelerate the development, validation, and uptake of New Approach Methodologies (NAMs) in biomedical research and regulatory testing. This call provides a total of EUR 2.90 million to fund a single overarching proposal that will harmonize strategies across Member States and Associated Countries for the 2025–2027 period. The project must facilitate an EU-wide forum involving ministries, regulatory agencies, academia, and the pharmaceutical industry. The action is structured around four primary Working Groups (WGs): WG1 (Development & Infrastructure): Identifying priority biological areas and infrastructures to leverage scientific strengths across different regions; WG2 (Validation & Uptake): Defining criteria for regulatory acceptance and prioritizing mature NAMs for qualification by the MedTech and pharmaceutical sectors; WG3 (Education & Training): Mapping and developing high-quality training modules on NAMs and the 3Rs principles (Replacement, Reduction, and Refinement) in partnership with knowledge institutes; WG4 (Openness & Awareness): Promoting open access to protocols and negative research results to prevent unnecessary duplication of animal testing and increasing regulator confidence in non-animal methods.

€9M – €44.2Mnon-repayable

Call for proposals to accelerate the development of vaccine candidates for emerging and re-emerging viral threats.

European Union

Call for proposals to accelerate the development of vaccine candidates for emerging and re-emerging viral threats. With a total budget of EUR 44.20 million, individual grants are expected to range between EUR 9.00 and 11.00 million. This initiative aims to diversify the global R&D portfolio and strengthen the EU’s leadership in pandemic preparedness, particularly as climate change accelerates the risk of viral disease emergence. Applicants must focus their proposal on advancing existing vaccine candidates for one of the following specific viruses: Mammarenaviruses: Junin or Lassa; Hantaviruses: Andes, Hantaan, or Sin Nombre; Other Emerging Viruses: Hendra, Enterovirus D68, or Venezuelan equine encephalitis. Proposals must address: Characterization and In-vivo Testing: Finalizing in-vitro characterization and conducting in-vivo protection tests in animal models (including non-human primates if requested by regulators); GMP Manufacturing: Producing batches of the most promising candidates according to Good Manufacturing Practices (GMP); Clinical Safety: Executing first-in-human clinical safety studies that outline a clear regulatory pathway; as well as Inclusive Research: Analyzing immune response and efficacy with attention to critical factors such as sex, age, disability, and ethnicity. For instance, researchers should note that vaccine responses can vary across ethnic groups; some studies have indicated that certain populations, such as those of African descent, may show different antibody titer levels or adverse event profiles compared to Caucasian populations, necessitating diverse clinical trial recruitment.

Call for proposals to support projects that aim to drive the integration of New Approach Methodologies (NAMs) across the biomedical and chemical safety spectrum.

European Union

€5M – €49Mnon-repayable

Call for proposals to support projects that aim to drive the integration of New Approach Methodologies (NAMs) across the biomedical and chemical safety spectrum. With a total budget of EUR 49.00 million, the call provides grants between EUR 5.00 and 8.00 million to support projects that reduce reliance on animal testing while enhancing the human relevance of drug discovery and regulatory assessments. Proposals should focus on developing or optimizing scalable, reproducible platforms that utilize cutting-edge technologies. These include: Complex In-Vitro Models: Utilizing induced Pluripotent Stem Cells (iPSC), patient-derived organoids, and sophisticated Organ-on-Chip (OoC) systems; Digital Innovation: Incorporating AI-driven predictive modeling and Virtual Twin technology to simulate disease progression and intervention responses; and Real-time Monitoring: Integrating embedded sensors to capture immediate physiological responses.

Call for proposals to establish a coordinated network of Centres of Excellence (CoEs) for Advanced Therapy Medicinal Products (ATMPs).

European Union

€3.9Mnon-repayable

Call for proposals to establish a coordinated network of Centres of Excellence (CoEs) for Advanced Therapy Medicinal Products (ATMPs). With a total budget of EUR 3.90 million, this call seeks to consolidate Europe's scattered innovation hubs into a world-class ecosystem capable of competing globally in the development of gene therapies, cell therapies, and tissue-engineered products. The initiative aims to bridge the gap from laboratory discovery to patient delivery by supporting existing centres embedded within vibrant bioclusters. Selected CoEs must already possess critical infrastructure, including state-of-the-art Good Manufacturing Practice (GMP) facilities and clinical trial capabilities. The network is intended to be limited to a maximum of 10 centres across the EU, each offering complementary expertise to ensure comprehensive coverage of various ATMP technologies. Proposed projects, spanning the period of 2027–2030, must address the following mandates: Policy and Harmonization: Develop recommendations for clinical trials, logistics, and the harmonization of market access and reimbursement procedures; Long-term Vision: Create a roadmap with clear milestones to position Europe as a global leader in ATMP research and innovation by 2035; Stakeholder Engagement: Establish a diverse advisory board and foster a multi-sectoral consortium including regulators, industry actors, and patient organizations; and Education: Design training programs for the next generation of scientists and conduct outreach to improve public understanding of advanced therapies.

€6M – €39.3Mnon-repayable

Call for proposals to address the significant sex and gender disparities in cardiovascular diseases (CVDs), which accounted for over 1.

European Union

Call for proposals to address the significant sex and gender disparities in cardiovascular diseases (CVDs), which accounted for over 1.7 million deaths (32% of all deaths) in the EU in 2021. With a total budget of EUR 39.30 million, the call offers individual awards between EUR 6.00 and 7.00 million to support projects that translate basic biological discoveries into innovative prevention, diagnosis, and treatment strategies tailored to specific physiological and sociocultural needs. Proposals are expected to further the understanding of structural, hormonal, and biological distinctions between sexes. Key focus areas include: Tailored Risk Models: Developing sex-specific models for better disease detection and prevention; Determinant Identification: Validating health determinants by integrating data from disciplines like molecular biology, genetics, and social epidemiology; Data Integration: Utilizing existing health registries, cohorts, and biobanks while ensuring any new data adheres to FAIR principles; and Technological Innovation: Encouraging the use of advanced tools, including Generative AI, to support research outcomes.

€6M – €39.3Mnon-repayable

Call for proposals to support projects that aim at mitigating the long-term health and economic impacts of persistent conditions resulting from microbial infections (excluding cancer).

European Union

Call for proposals to support projects that aim at mitigating the long-term health and economic impacts of persistent conditions resulting from microbial infections (excluding cancer). With a total budget of EUR 39.30 million, this initiative seeks to award individual grants between EUR 6.00 and 8.00 million to projects that improve the prevention, diagnosis, and management of these often underdiagnosed conditions. Proposals should adopt a multidisciplinary approach to identify risk and protective factors—such as genetics and inflammatory responses—and increase our understanding of disease pathophysiology. Key research areas include: Developing clinically validated diagnostic tools and biomarkers; Conducting early-stage clinical trials for preventive or therapeutic interventions; Identifying effective rehabilitation strategies, including physical and cognitive therapies; and Integrating disease management into primary and specialized healthcare settings.